Bridge Neurotech raises $13.5 million for a non-invasive ultrasound brain interface
Founded by former Forest Neurotech co-founder Will Biederman, the start-up is backed by General Catalyst, has licensed Butterfly Network's ultrasound chips and is enrolling its first human study.
Silicon Valley start-up Bridge Neurotech announced on October 7 that it has raised $13.5 million from General Catalyst, reMind Capital, Sunflower Capital and investor Scott Sandell. The company is building a brain-computer interface that needs no surgery: it uses functional ultrasound imaging, which tracks blood flow as a stand-in for neural activity, and AI models to decode the signals. Founder Will Biederman previously worked at Verily and co-founded Forest Neurotech. Bridge also signed a multi-year license for Butterfly Network’s ultrasound-on-chip technology (terms undisclosed) and is enrolling healthy adults in a first study in Redwood City, California.
Ultrasound is drawing investment as a middle path between implants and EEG, with Merge Labs and Gestala pursuing related ideas. Imaging through an intact skull at useful resolution remains unproven, and Bridge has not yet published human data.
Learn more: Merge Labs signs ultrasound-chip deal with Butterfly Network · Invasive vs. non-invasive